Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma

Εμφάνιση άλλων εκδόσεων (1)

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Croucher, P, Shipman, C, Perry, M, Lippitt, J, Asosingh, K, van Beek, E, Van Camp, B, Russell, R, Dunstan, C, Vanderkerken, K
Μορφή:	Journal article
Έκδοση:	2001

Παρόμοια τεκμήρια

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.
ανά: Croucher, P, κ.ά.
Έκδοση: (2001)

Osteoprotegerin (OPG) inhibits the development of osteolytic bone disease in the 5T2MM model of multiple myeloma.
ανά: Croucher, P, κ.ά.
Έκδοση: (2000)

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
ανά: Croucher, P, κ.ά.
Έκδοση: (2003)

Zoledronic acid inhibits the development of osteolytic bone disease and increases disease free survival in a murine model of multiple myeloma.
ανά: Croucher, P, κ.ά.
Έκδοση: (2001)

Osteoprotegerin and the development of myeloma bone disease
ανά: Croucher, P, κ.ά.
Έκδοση: (2004)

Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma.
ανά: Vanderkerken, K, κ.ά.
Έκδοση: (2003)

Zoledronic acid prevents the development of osteolytic bone disease and increases survival in a murine model of multiple myeloma
ανά: Croucher, P, κ.ά.
Έκδοση: (2002)

Myeloma cells can down-regulate release of osteoprotegerin (OPG) from human bone cells - A contributing factor in myeloma bone loss?
ανά: Shipman, C, κ.ά.
Έκδοση: (2002)

Bone marrow endothelial cells produce osteoprotegerin: Evidence for a role in the development of myeloma bone disease
ανά: De Leenheer, E, κ.ά.
Έκδοση: (2004)

Myeloma cells isolated from patients with multiple myeloma express osteoprotegerin ligand.
ανά: Shipman, C, κ.ά.
Έκδοση: (2000)

The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma.
ανά: Shipman, C, κ.ά.
Έκδοση: (2000)

Zoledronic acid prevents the development of myeloma bone disease and increases survival
ανά: Shipman, C, κ.ά.
Έκδοση: (2002)

Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.
ανά: Croucher, P, κ.ά.
Έκδοση: (2003)

Bisphosphonates--mechanisms of action in multiple myeloma.
ανά: Shipman, C, κ.ά.
Έκδοση: (2000)

Bisphosphonates and in vivo models of multiple myeloma - Reply
ανά: Shipman, C, κ.ά.
Έκδοση: (2001)

APOMINE (TM), a novel inhibitor of the meyalonate/isoprenoid pathway, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of the myeloma disease in vivo.
ανά: Croucher, P, κ.ά.
Έκδοση: (2002)

Bone marrow endothelial cells express the osteoclastogenic factor RANKL and its decoy receptor OPG: Evidence for a role in the development of myeloma bone disease.
ανά: De Leenheer, E, κ.ά.
Έκδοση: (2002)

Osteoprotegerin (OPG) is a soluble decoy receptor for TRAIL/Apo2L and can inhibit TRAIL/Apo2L-induced apoptosis of human myeloma cells in vitro.
ανά: Shipman, C, κ.ά.
Έκδοση: (2002)

Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
ανά: Shipman, C, κ.ά.
Έκδοση: (2003)

Tumour cells isolated from patients with multiple myeloma express the critical osteoclastogenic factor, RANKL.
ανά: Shipman, C, κ.ά.
Έκδοση: (2000)

Osteocyte CIITA aggravates osteolytic bone lesions in myeloma
ανά: Huan Liu, κ.ά.
Έκδοση: (2022-06-01)

Elucidation of molecular basis of osteolytic bone lesions in advanced multiple myeloma
ανά: Dongyeop Shin, κ.ά.
Έκδοση: (2024-01-01)

RANKL/RANK/osteoprotegerin system as novel therapeutic target in the treatment of primary bone tumors and osteolytic metastases
ανά: Anđelković Zlatibor, κ.ά.
Έκδοση: (2004-01-01)

The role of osteoprotegerin in breast and prostate cancer
ανά: Holen, I, κ.ά.
Έκδοση: (2002)

CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
ανά: Dongzheng Gai, κ.ά.
Έκδοση: (2022-09-01)

Osteolytic lesions: Multiple myeloma or prostate cancer?
ανά: Akshitha Devaraj, MBBS, κ.ά.
Έκδοση: (2023-04-01)

Preventing osteolytic lesions and osteomyelitis in multiple myeloma
ανά: Aiken Dao, κ.ά.
Έκδοση: (2022-12-01)

Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma
ανά: Dirk Hose, κ.ά.
Έκδοση: (2024-12-01)

Soluble rank ligand produced by myeloma cells causes generalised bone loss in multiple myeloma.
ανά: Clive Henry Buckle, κ.ά.
Έκδοση: (2012-01-01)

Role of osteoprotegerin (OPG) in cancer.
ανά: Holen, I, κ.ά.
Έκδοση: (2006)

Myeloma cells can promote osteoclastic activity rather than osteoclast recruitment in vitro; Evidence from the 5T2MM murine model of myeloma
ανά: Mueller, G, κ.ά.
Έκδοση: (2004)

Cells of the bone marrow microenvironment protect myeloma cells from apoptosis induced by TRAIL but not by agonists of TRAIL death receptors.
ανά: Locklin, R, κ.ά.
Έκδοση: (2005)

5T2MM murine myeloma cells and CD138+ve human myeloma cells promote osteoclastic activity rather than osteoclast formation in vitro
ανά: Mueller, G, κ.ά.
Έκδοση: (2004)

Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo.
ανά: Edwards, C, κ.ά.
Έκδοση: (2007)

Correction: Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma
ανά: Dirk Hose, κ.ά.
Έκδοση: (2025-01-01)

Multiple myeloma presenting as a massive osteolytic lesion at the clivus
ανά: Domingos Sousa, κ.ά.
Έκδοση: (2020-11-01)

The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway.
ανά: Shipman, C, κ.ά.
Έκδοση: (1998)

Promotion of Bone Lesions Through the Myeloma Integrin α6-Mediated Osteolytic Signaling
ανά: Huan Liu, κ.ά.
Έκδοση: (2021-06-01)

A loss of host-derived MMP-7 promotes myeloma growth and osteolytic bone disease in vivo
ανά: Lwin, S, κ.ά.
Έκδοση: (2017)

Metastatic breast cancer with osteolytic skull lesions suspected to be multiple myeloma
ανά: Young Mo Kang, κ.ά.
Έκδοση: (2017-12-01)